171 related articles for article (PubMed ID: 33641872)
1. Accelerated and Blast Phase Myeloproliferative Neoplasms.
Jain T; Rampal RK
Hematol Oncol Clin North Am; 2021 Apr; 35(2):325-335. PubMed ID: 33641872
[TBL] [Abstract][Full Text] [Related]
2. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
3. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.
Tam CS; Nussenzveig RM; Popat U; Bueso-Ramos CE; Thomas DA; Cortes JA; Champlin RE; Ciurea SE; Manshouri T; Pierce SM; Kantarjian HM; Verstovsek S
Blood; 2008 Sep; 112(5):1628-37. PubMed ID: 18566326
[TBL] [Abstract][Full Text] [Related]
4. Accelerated and blast phase myeloproliferative neoplasms.
Saliba AN; Gangat N
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
[TBL] [Abstract][Full Text] [Related]
5. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
Kundranda MN; Tibes R; Mesa RA
Curr Hematol Malig Rep; 2012 Mar; 7(1):78-86. PubMed ID: 22170483
[TBL] [Abstract][Full Text] [Related]
6. Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond.
Saha C; Attwell L; Harrison CN; McLornan DP
Blood Rev; 2022 Sep; 55():100947. PubMed ID: 35241294
[TBL] [Abstract][Full Text] [Related]
7. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.
Bewersdorf JP; Rampal RK
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):218-224. PubMed ID: 36485103
[TBL] [Abstract][Full Text] [Related]
8. MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report.
He Z; Wang B; Chen L; Huang Y; Wang H; Yang M; Xiao X; Lu Y; Chen J; Wu Y
Medicine (Baltimore); 2018 Nov; 97(46):e13220. PubMed ID: 30431598
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms.
Castillo Tokumori F; Al Ali N; Chan O; Sallman D; Yun S; Sweet K; Padron E; Lancet J; Komrokji R; Kuykendall AT
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e521-e525. PubMed ID: 35241387
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era.
Shah MV; Saliba RM; Varma A; Ciurea SO; Oran B; Olson A; Bose P; Bashir Q; Masarova L; Alousi AM; Srour S; Mehta RS; Daver N; Pemmaraju N; Verstovsek S; Champlin RE; Popat UR
Br J Haematol; 2021 Jun; 193(5):1004-1008. PubMed ID: 33821472
[No Abstract] [Full Text] [Related]
11. Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?
Mahdi D; Spiers J; Rampotas A; Polverelli N; McLornan DP
Br J Haematol; 2023 Oct; 203(2):169-181. PubMed ID: 37527977
[TBL] [Abstract][Full Text] [Related]
12. Relapse and cytogenetic evolution in myeloid neoplasms.
Ertz-Archambault N; Kelemen K
Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
[TBL] [Abstract][Full Text] [Related]
13. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.
Mascarenhas J; Heaney ML; Najfeld V; Hexner E; Abdel-Wahab O; Rampal R; Ravandi F; Petersen B; Roboz G; Feldman E; Podoltsev N; Douer D; Levine R; Tallman M; Hoffman R;
Leuk Res; 2012 Dec; 36(12):1500-4. PubMed ID: 22938832
[TBL] [Abstract][Full Text] [Related]
14. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options.
Iurlo A; Cattaneo D; Gianelli U
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013941
[TBL] [Abstract][Full Text] [Related]
15. Current clinical strategies and emergent treatment landscapes in leukemic transformation of Philadelphia-negative myeloproliferative neoplasms.
Abruzzese E; Niscola P
Expert Rev Hematol; 2020 Dec; 13(12):1349-1359. PubMed ID: 33226274
[No Abstract] [Full Text] [Related]
16. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.
Cherington C; Slack JL; Leis J; Adams RH; Reeder CB; Mikhael JR; Camoriano J; Noel P; Fauble V; Betcher J; Higgins MS; Gillette-Kent G; Tremblay LD; Peterson ME; Olsen JJ; Tibes R; Mesa RA
Leuk Res; 2012 Sep; 36(9):1147-51. PubMed ID: 22578777
[TBL] [Abstract][Full Text] [Related]
17. How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms.
Odenike O
Blood; 2018 Nov; 132(22):2339-2350. PubMed ID: 30333119
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Gangat N; Guglielmelli P; Szuber N; Begna KH; Patnaik MM; Litzow MR; Al-Kali A; Foran JM; Palmer JM; Alkhateeb H; Elliott MA; Hanson CA; Pardanani A; Mannelli F; Vannucchi AM; Tefferi A
Am J Hematol; 2021 Jul; 96(7):781-789. PubMed ID: 33844862
[TBL] [Abstract][Full Text] [Related]
19. Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase.
Mollard LM; Chauveau A; Boyer-Perrard F; Douet-Guilbert N; Houot R; Quintin-Roué I; Couturier MA; Dagorne A; Malou M; Le Calloch R; Luycx O; Thepot S; Hunault M; Guillerm G; Berthou C; Ugo V; Lippert É; Ianotto JC
Leuk Lymphoma; 2018 Dec; 59(12):2812-2820. PubMed ID: 29616837
[TBL] [Abstract][Full Text] [Related]
20. Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.
Gupta V; Kim S; Hu ZH; Liu Y; Aljurf M; Bacher U; Beitinjaneh A; Cahn JY; Cerny J; Copelan E; Gadalla SM; Gale RP; Ganguly S; George B; Gerds AT; Gergis U; Hamilton BK; Hashmi S; Hildebrandt GC; Kamble RT; Kindwall-Keller T; Lazarus HM; Liesveld JL; Litzow M; Maziarz RT; Nishihori T; Olsson RF; Rizzieri D; Savani BN; Seo S; Solh M; Szer J; Verdonck LF; Wirk B; Woolfrey A; Yared JA; Alyea EP; Popat UR; Sobecks RM; Scott BL; Nakamura R; Saber W
Blood Adv; 2020 Oct; 4(19):4748-4757. PubMed ID: 33007075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]